Saturday, November 08, 2014 9:03:43 PM
Roka Bioscience (NASDAQ:ROKA) was downgraded by Wedbush from an “outperform” rating to a “neutral” rating in a research note issued on Friday, TheFlyOnTheWall.com reports. They currently have a $9.00 target price on the stock, down from their previous target price of $15.00.
A number of firms have recently commented on ROKA. Analysts at Bank of America downgraded shares of Roka Bioscience from a “buy” rating to a “neutral” rating in a research note on Friday. They now have a $8.50 price target on the stock, down previously from $14.00. Finally, analysts at Cowen and Company initiated coverage on shares of Roka Bioscience in a research note on Monday, August 11th. They set an “outperform” rating and a $13.00 price target on the stock.
Shares of Roka Bioscience (NASDAQ:ROKA) opened at 3.00 on Friday. Roka Bioscience has a 52 week low of $2.97 and a 52 week high of $13.00. The stock has a 50-day moving average of $9.36 and a 200-day moving average of $10.30. The company’s market cap is $53.0 million.
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM